Segurança do ocrelizumabe no tratamento da esclerose múltipla: efeitos adversos e riscos associados ao uso prolongado
Revista ft · 2026-10-31 · 30 (163) · 01-07
DOI: 10.69849/vxcbpp15 ↗At a glance
Journal article in Revista ft, published online on 2026-10-31. Written by Maria Eduarda Santana Bruneto and 1 co-authors. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Ocrelizumab, an anti-CD20 monoclonal antibody used in the treatment of multiple sclerosis, has established efficacy but requires careful attention to safety during long-term exposure. This article analyzes six clinical and observational publications published between 2017 and 2026. It can be observed that the use of this medication leads to a reduction in immunoglobulin levels, particularly IgM, and is associated with a higher frequency of infections requiring antibiotic treatment. Other adverse events associated with the use of this medication include infusion related reactions and infections, which require specific care and monitoring.
Cite
APA
Bruneto, M. E. S., & Bruneto, J. V. S. (2026). Segurança do ocrelizumabe no tratamento da esclerose múltipla: efeitos adversos e riscos associados ao uso prolongado. Revista ft, 30(163), 01-07. https://doi.org/10.69849/vxcbpp15
Vancouver
Bruneto MES, Bruneto JVS. Segurança do ocrelizumabe no tratamento da esclerose múltipla: efeitos adversos e riscos associados ao uso prolongado. Revista ft. 2026;30(163):01-07. doi:10.69849/vxcbpp15
BibTeX
@article{Bruneto2026,
author = {Bruneto, Maria Eduarda Santana and Bruneto, João Victor Santana},
title = {Segurança do ocrelizumabe no tratamento da esclerose múltipla: efeitos adversos e riscos associados ao uso prolongado},
journal = {Revista ft},
year = {2026},
volume = {30},
number = {163},
pages = {01--07},
doi = {10.69849/vxcbpp15}
}
EUVIMED